SHAREHOLDER ACTION NOTICE: Faruqi & Faruqi, LLP Notifies Vistagen (VTGN) Investors of the Pending Class Action Lawsuit

Core Viewpoint - The complaint against Vistagen alleges violations of federal securities laws due to false or misleading statements regarding the Phase 3 PALISADE-3 trial of fasedienol for treating social anxiety disorder [2] Group 1: Company Performance - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, failing to show statistically significant improvement in anxiety reduction compared to placebo [3] - Following the announcement, Vistagen's stock price dropped by $3.50, a decline of 80.27%, closing at $0.86 [3] Group 2: Legal Proceedings - The lead plaintiff in the class action is the investor with the largest financial interest in the case, who will oversee the litigation on behalf of the class [4] - Any member of the class can apply to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [4] Group 3: Whistleblower Information - The law firm Faruqi & Faruqi encourages individuals with information regarding Vistagen's conduct, including whistleblowers and former employees, to come forward [5]